Prehabilitation in Patients With Cancer and Type 2 Diabetes
Launched by UNIVERSITY OF GREENWICH · Sep 15, 2022
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a special program called "prehabilitation" for patients who have both cancer and Type 2 diabetes that doesn't require insulin. Prehabilitation involves preparing patients for surgery through a combination of healthy lifestyle changes, such as exercise, nutrition education, and strategies to manage anxiety. The goal is to help patients feel stronger and healthier before their surgery, which may lead to better recovery and overall well-being. The trial will compare this multimodal prehabilitation program to the usual care provided by the NHS.
To be eligible for this trial, participants must be between 65 and 74 years old, have recently been diagnosed with cancer, and are scheduled for surgery. They must also be able to understand and agree to participate in the study. During the trial, participants can expect to engage in activities aimed at improving their physical fitness and overall health, while also having their progress monitored for up to 12 months after surgery. This study hopes to provide valuable insights into how prehabilitation can benefit patients with both cancer and Type 2 diabetes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Capacity to give consent
- • Newly diagnosed with cancer
- • Non-insulin-dependent Type 2 diabetes
- • Awaiting surgery for cancer
- Exclusion Criteria:
- • Medical contraindication to engage in physical activity
About University Of Greenwich
The University of Greenwich is a leading academic institution dedicated to advancing knowledge and innovation through rigorous research and clinical trials. With a commitment to high standards of ethical practice and scientific integrity, the university fosters interdisciplinary collaboration among its faculty and students to address pressing health challenges. By leveraging its state-of-the-art facilities and expertise, the University of Greenwich aims to contribute valuable insights to the medical field, enhance patient outcomes, and support the development of new therapies through robust clinical trial methodologies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Eltham, England, United Kingdom
Patients applied
Trial Officials
Fernando Naclerio, PhD
Principal Investigator
University of Greenwich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials